Nanobiotix S.A. (NASDAQ:NBTX) Short Interest Up 37.6% in February

Nanobiotix S.A. (NASDAQ:NBTX) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 29,300 shares, an increase of 37.6% from the February 13th total of 21,300 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 32,500 shares, the short-interest ratio is presently 0.9 days.

Wall Street Analysts Forecast Growth

Separately, UBS Group upgraded Nanobiotix to a “hold” rating in a report on Monday, February 17th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new position in Nanobiotix in the fourth quarter valued at approximately $39,000. Jane Street Group LLC acquired a new position in Nanobiotix in the fourth quarter valued at approximately $73,000. Geode Capital Management LLC acquired a new position in Nanobiotix in the fourth quarter valued at approximately $29,000. Finally, OLD Mission Capital LLC acquired a new position in Nanobiotix in the fourth quarter valued at approximately $139,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

Nanobiotix Trading Up 4.9 %

Shares of Nanobiotix stock traded up $0.15 on Friday, hitting $3.22. 388 shares of the company were exchanged, compared to its average volume of 22,032. The company has a 50-day moving average price of $3.43 and a 200 day moving average price of $3.97. Nanobiotix has a 1-year low of $2.76 and a 1-year high of $7.51.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.